P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novan, Inc.

Criteria

Inclusion Criteria:

• Moderate to severe acne

• 25-70 non-inflammatory lesions at Baseline

• 20-40 inflammatory lesions at Baseline

Exclusion Criteria:

• Subjects with known allergy to any component of the test material or vehicle

• Women who are pregnant or nursing